Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer: a meta-analysis

Abstract

BackgroundThe prognostic effect of pretreatment elevated platelet count remains controversial in colorectal cancer patients. We conducted this meta-analysis to evaluate the prognostic impact of it in these patients.MethodsPubMed, EMBASE and Cochrane Library were searched and studies on the prognostic significance of pretreatment elevated platelet count in colorectal patients were identified. We performed the meta-analysis, using overall survival and disease-free survival as outcomes and presenting data with hazard ratio and its 95% confidence interval. Heterogeneity among studies and publication bias were also evaluated.ResultsThirty studies were included in the meta-analysis. Compared with normal platelet count, pretreatment elevated platelet count was associated with poorer overall survival (Hazard ratio = 1.837, 95% confidence interval, 1.497 to 2.255, p = 0.000) and poorer disease-free survival (Hazard ratio = 1.635, 95% confidence interval, 1.237 to 2.160, p = 0.001) in patients with colorectal cancer. In subgroup analyses, pretreatment elevated platelet count was also associated with poorer overall survival and disease-free survival in most subgroups.ConclusionPretreatment elevated platelet count was an independent prognostic factor of overall survival and disease-free survival in colorectal cancer patients. Large-scale prospective studies and a validation study are warranted.

Platelet count and platelet‐lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta‐analysis

“…62 These interactions between tumor cells and platelets contribute to poor prognosis in patients with cancer. 19,20,[23][24][25][26][27][28]30,32,33,63 Studies regarding HNSCC, most of which have been published over the past few years (Tables 1 34-40,51 and 2 37,38,[41][42][43][44][45][46]51 ), showed differing disease sites, stage of disease, treatment modalities, cutoff values, and primary end points. 15,16 An increasing number of studies are investigating the association between thrombocytosis and mortality in patients with cancer.…”

“…15,16 An increasing number of studies are investigating the association between thrombocytosis and mortality in patients with cancer. 19,20,[23][24][25][26][27][28]30,32,33,63 Studies regarding HNSCC, most of which have been published over the past few years (Tables 1 [34][35][36][37][38][39][40]51 and 2 37,38,[41][42][43][44][45][46]51 ), showed differing disease sites, stage of disease, treatment modalities, cutoff values, and primary end points. Thus, the reported impact of elevated platelet count and PLR differs significantly among studies.…”

“…Tissue specimens allow for the direct examination of tumor and stromal cells. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Although the association between these markers and HNSCC prognosis has been investigated, the results have been inconsistent. However, blood samples can easily be obtained at any time, and blood markers can be measured repeatedly.…”

“…14 Platelet count and plateletlymphocyte ratio (PLR) are hematologic makers that have shown prognostic abilities across many types of cancers. [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Although the association between these markers and HNSCC prognosis has been investigated, the results have been inconsistent. [34][35][36][37][38][39][40][41][42][43][44][45][46] Among these studies, only 1 study was prospective.…”

Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients

“…Activated platelets also release pro-inflammatory mediators which interfere in the pathophysiology of MetS 42. The latest meta-analysis reported that elevated platelet count and thrombocytosis prior to treatment, was related with a poor prognosis for patients with CRC 43,44. Lymphocytes play a vital role in cancer immune surveillance and suppress tumor maturation 45.…”